In collaboration with several Swiss University and Cantonal Hospital Centers, the monitoring of their imatinib plasma levels (i.e. therapeutic drug monitoring, TDM) was evaluated for all Swiss CML patients treated with imatinib since < 5 years. This service was offered in relation with a prospective study:
Results from this study will soon be available.
The study has been approved from the local Ethics Committee in the following Swiss cantons:
AG, AI, BE, BS/BL, FR, GE, GL, GR, JU, LU, NE, NW/OW, SG, SH, SO, SZ, TI, TG, UR, VD, VS, ZH, ZG.
It has also been approved in the Principality of Liechtenstein (LI).
Centre Hospitalier Universitaire Vaudois (study sponsor) – Novartis (grant in aid)